Earlier this month, Eli Lilly and Boehringer Ingelheim presented data from their Phase 2 studies comparing their lead basal insulin analog candidate, LY2605541, with Sanofi-Aventis's billion-dollar product, Lantus. With improved or equal...
Contact us to learn the benefits of becoming a Lux member.
Or call us now
For North America (Boston Headquarters)
+1 (617) 502-5300
For EMEA (Amsterdam)
+31 20 280 7900
For APAC (Singapore)